Liverpool platform will support nanomedicine developers
A new platform to support companies that are developing cutting-edge treatments for infectious diseases has been established at the University of Liverpool.
A new agreement will see The Nanotherapeutics Hub, part of Liverpool’s Centre of Excellence for Long-acting Therapeutics (CELT), work with the Infection Innovation Consortium (iiCON) to support the development of nanomedicines.
Nanomedicine is the application of nanomaterials, or nanoparticles, to medicine. Nanoparticles are a form of delivery for drugs that can reach places drugs normally couldn’t reach otherwise. It is a market projected to be worth more than £150bn by 2026.
Led by the Liverpool School of Tropical Medicine (LSTM) and backed by UKRI’s Strength in Places Fund (SIPF), iiCON is revitalising the UK’s infectious diseases product pipeline.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.